{"links":{"feed":"https://www.erudio.com/reports/rezilient1-nct04036682/feed.json","html":"https://www.erudio.com/reports/rezilient1-nct04036682","json":"https://www.erudio.com/reports/rezilient1-nct04036682.json","markdown":"https://www.erudio.com/reports/rezilient1-nct04036682.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rezilient1-nct04036682"}},"request":"https://www.erudio.com/contact?report=rezilient1-nct04036682"},"offer":{"cited_clinicians":21,"cited_commentary_sources":56,"verified_hcp_statements":129,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":26},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12"],"report":"rezilient1-nct04036682"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rezilient1-nct04036682","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rezilient1-nct04036682","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 129 verified statements · 58 from 21 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-10T23:09:07.460520Z","notify_subscribers":false,"status":"corrected","summary":"The count of statements from confirmed clinicians now follows the people cards."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":17,"no_commentary_found":3},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: All Cohorts: The rate and severity of treatment emergent AEs."},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: All Cohorts: The rate and severity of DLTs."},{"claim_count":18,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":15,"title":"Primary endpoint: Phase 2 Dose Expansion Cohorts: Overall response rate (ORR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":0,"title":"Primary endpoint: Module A: Pharmacokinetic (PK) parameter"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.primaryOutcomes[4]","source_count":0,"title":"Primary endpoint: Module A: Pharmacokinetic (PK) parameter"},{"claim_count":21,"coverage":"discussed","id":"T6","registry_field":"outcomesModule.primaryOutcomes[5]","source_count":18,"title":"Primary endpoint: Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC)"},{"claim_count":12,"coverage":"discussed","id":"T7","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":18,"coverage":"discussed","id":"T8","registry_field":"conditionsModule","source_count":13,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T9","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":24,"coverage":"discussed","id":"T10","registry_field":"armsInterventionsModule.interventions","source_count":20,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T11","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":19,"coverage":"discussed","id":"A1","source_count":14,"title":"Post-amivantamab sequencing, cross-resistance and repeated targeted therapy"},{"claim_count":14,"coverage":"discussed","id":"A2","source_count":14,"title":"CNS activity, endpoint wording and applicability"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":6,"title":"Oral treatment, patient priorities and clinic burden"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":1,"title":"Post-amivantamab alternatives, access constraints and case burden"},{"claim_count":9,"coverage":"discussed","id":"A6","source_count":8,"title":"First-line combination versus later-line placement"},{"claim_count":10,"coverage":"discussed","id":"A7","source_count":9,"title":"Regulatory interest, submission milestones and possible label scope"},{"claim_count":6,"coverage":"discussed","id":"A8","source_count":5,"title":"Mechanistic explanations, selectivity and resistance questions"},{"claim_count":17,"coverage":"discussed","id":"A9","source_count":14,"title":"Perceived treatment progress and the distinction between clinical and organizational reactions"},{"claim_count":23,"coverage":"discussed","id":"A10","source_count":8,"title":"Earlier CLN-081 phase 1/2a evidence and dose interpretation"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":26,"cited_clinicians":21,"cited_clinicians_by_role":{"physician":5,"physician, Hematology and oncology":1,"physician, Medical oncology":15},"cited_physicians":21,"cited_sources":58,"claims_by_expression_type":{"comparison":6,"experience":3,"interpretation":38,"opinion":27,"primary_context":4,"question":5,"restatement":24,"uncertainty":3,"unspecified":19},"claims_by_kind":{"interpretation":3,"objective_result":2,"protocol_statement":1,"publication_statement":4,"source_observation":119},"clinician_statements":58,"evidence_units":118,"findings":8,"organisational_accounts":13,"people_cited":31,"people_identity_verified":26,"people_total":31,"screened_sources":153,"verified_claims":129},"findings_index":[{"cited_clinicians":4,"id":"F1","structure":{"claims":19,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":4,"views":12},"limitations":4,"links":{"context":3,"support":19},"ma_question":true,"named_voices":7,"passages":11,"sources":10,"sources_by_kind":{"commentary":6,"media":3,"publication":1}},"title":"Speakers see a post-amivantamab sequencing opportunity; one account questions successive targeted therapies"},{"cited_clinicians":0,"id":"F2","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":3,"views":1},"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":0,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"publication":1}},"title":"One interview stresses that noncomparative activity cannot establish the better treatment"},{"cited_clinicians":8,"id":"F3","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":18},"limitations":3,"links":{"context":0,"support":25},"ma_question":true,"named_voices":8,"passages":18,"sources":17,"sources_by_kind":{"commentary":14,"media":2,"publication":1}},"title":"Speakers differ on zipalertinib response after pretreatment, discussing durability and safety; one cites CNS activity, another notes absent intracranial-response data and immature overall-survival data"},{"cited_clinicians":7,"id":"F4","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":8,"views":7},"limitations":4,"links":{"context":4,"support":19},"ma_question":true,"named_voices":6,"passages":17,"sources":15,"sources_by_kind":{"commentary":13,"media":1,"publication":1}},"title":"Speakers welcome possible CNS activity while emphasizing unresolved CNS-specific evidence"},{"cited_clinicians":7,"id":"F5","structure":{"claims":26,"claims_by_group":{"comparisons":3,"experience":0,"questions":1,"restated":10,"views":12},"limitations":4,"links":{"context":4,"support":29},"ma_question":true,"named_voices":5,"passages":25,"sources":21,"sources_by_kind":{"commentary":17,"media":2,"publication":2}},"title":"Speakers favor the safety profile; one interview challenges what “manageable” means"},{"cited_clinicians":4,"id":"F6","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":10},"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":2,"passages":9,"sources":7,"sources_by_kind":{"commentary":5,"media":2}},"title":"Speakers want more oral options; one interview emphasizes time, cost and quality of life"},{"cited_clinicians":2,"id":"F7","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":1,"views":3},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":2,"passages":7,"sources":1,"sources_by_kind":{"commentary":1}},"title":"One case discussion makes access and biomarker status decisive for the next line"},{"cited_clinicians":1,"id":"F8","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":8,"views":1},"limitations":4,"links":{"context":0,"support":13},"ma_question":true,"named_voices":1,"passages":9,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"One clinician asks about approval; nonclinical accounts describe a conditional regulatory path"}],"open_question":{"basis":"From finding F1 (19 statements from 7 speakers in 10 sources)","cited_claim_ids":["claim-951b24be2336b89f9d1b","claim-84683a5b58bee3c78f1d","claim-c26b2e6e27c89fd35e80","claim-5ee735301221a5b00ec3","claim-add7883ae7cf5acc40ac","claim-adb6a0f44afa4ddbe480","claim-9d4a3a3dd66f723a5621","claim-cca13aba6c2805605991","claim-bc49d8c85e229121dd5d","claim-4dfaaf99e000cb88a590","claim-9165756f363a2a12d715","claim-1c121bb2d98db557a57e","claim-ceeb36c52170501ac844","claim-0d82770e5f408b0bab3a","claim-8615a5317878c1481cb2"],"finding_ids":["F1"],"question":"What evidence on overall survival and cross-resistance do clinicians say is needed to define zipalertinib’s place after amivantamab in previously treated EGFR exon 20 insertion-positive metastatic NSCLC, with or without prior exon 20–targeting TKI exposure?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers see a post-amivantamab opportunity, not an established optimal sequence"},{"id":"section-2","level":2,"title":"One interview explicitly limits comparative conclusions"},{"id":"section-3","level":2,"title":"Speakers differ over the clinical weight of the activity"},{"id":"section-4","level":2,"title":"Speakers welcome a CNS signal but distinguish inference from a CNS endpoint"},{"id":"section-5","level":2,"title":"Speakers favor tolerability while preserving dose, severity and patient-burden qualifications"},{"id":"section-6","level":2,"title":"Speakers want oral options for reasons beyond response alone"},{"id":"section-7","level":2,"title":"One case discussion shows why a preferred option may not be used"},{"id":"section-8","level":2,"title":"One clinician asks about approval while other accounts describe milestones"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"Speakers leave first-line combination versus later-line placement unresolved"},{"id":"section-11","level":3,"title":"Speakers favor molecular work-up and leave mechanistic and co-alteration questions open"},{"id":"section-12","level":2,"title":"Scope and coverage of the discussion"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1, phase2","trial_dimensions":[{"findings":[{"id":"F5","shared_claims":9}],"id":"T1","label":"Primary endpoint: All Cohorts: The rate and severity of treatment emergent AEs."},{"findings":[],"id":"T2","label":"Primary endpoint: All Cohorts: The rate and severity of DLTs."},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":9},{"id":"F4","shared_claims":6},{"id":"F5","shared_claims":2}],"id":"T3","label":"Primary endpoint: Phase 2 Dose Expansion Cohorts: Overall response rate (ORR)"},{"findings":[],"id":"T4","label":"Primary endpoint: Module A: Pharmacokinetic (PK) parameter"},{"findings":[],"id":"T5","label":"Primary endpoint: Module A: Pharmacokinetic (PK) parameter"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":7},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T6","label":"Primary endpoint: Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":7},{"id":"F4","shared_claims":6}],"id":"T7","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":5},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":2}],"id":"T8","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F5","shared_claims":2}],"id":"T9","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":23},{"id":"F6","shared_claims":2}],"id":"T10","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":3},{"id":"F5","shared_claims":1}],"id":"T11","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-10T23:09:07.460520Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-11T00:16:30Z","record_hash":"22ee028539215a371592e32bc1b9a4dc9dd855ef2fb2a7adce72ac7fa649ef7c","release_hash":"772652623cff9443f83f7573b5933272615e5fe53e06e4dbe267264335d139ba","report_id":"erudio-nct04036682","run_id":"c5e045f5-210d-4b8a-8fa8-cb7fcdfb1453","schema_version":"5.0","slug":"rezilient1-nct04036682","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist described in the sources as presenting REZILIENT1 sees zipalertinib as a possible further treatment line because activity was observed after amivantamab, but notes lower response rates after amivantamab plus another exon20-targeting drug. Another speaker thinks one targeted therapy is probably enough. Comparative benefit remains unproven, and responses in patients with brain metastases do not establish CNS-specific benefit.","examples":[],"meta_description":"153 sources screened · 129 verified statements (58 from clinicians verified by NPI or staff page) from 58 sources · 8 findings. Updated Nov 10, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-11T00:16:30Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-11T00:39:09Z","kind":"routine","summary":"The count of statements from confirmed clinicians now follows the people cards."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":153},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","193 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 31 sources about other trials or topics are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion. Unnamed trial references and alternative wording may be missing, and one identified X discussion was unavailable.","Social posts, presentation relays, reposts, organizational coverage and investment-focused commentary are not independent HCP observations or a basis for measuring consensus.","Some interview speech remains unidentified. Guest descriptions, author lists and professional profiles do not establish who spoke those passages.","Clinical-role information is unavailable for several named authors. Identity or research associations do not increase the evidentiary weight of a view.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The early phase 1/2a data, early post-amivantamab Module C analysis and later publication use different populations and follow-up. Their estimates cannot be combined into a single result or trend.","Some accounts contain unresolved endpoint labels, subgroup misassignments or internally inconsistent summaries. These remain attributed statements rather than corrected facts.","Overall response among patients with brain metastases, intracranial response, CNS penetration and activity in unstable or symptomatic CNS disease are different questions.","All-grade, high-grade, treatment-related and unspecified adverse-event percentages are not interchangeable. Subjective comparisons do not establish comparative safety.","No exact regulatory label or standalone protocol document was available. Submission plans, NDA acceptance and target action dates do not establish approval or label breadth.","No commentary specifically addressing Module A pharmacokinetic parameters or reported dose-limiting-toxicity rates was identified in the reviewed material."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":0,"publication":2,"registry":0,"regulatory":0,"x_thread":50,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":56,"context":1,"results":1},"count":58,"evidence_window":{"end":"2026-10-17","start":"2022-05-26"},"retrieval_snapshot":"2026-11-10T21:53:48.308534Z","timeline":[{"count":1,"week":"2022-W21"},{"count":3,"week":"2022-W22"},{"count":1,"week":"2022-W28"},{"count":1,"week":"2022-W29"},{"count":1,"week":"2023-W26"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2023-W31"},{"count":1,"week":"2024-W21"},{"count":2,"week":"2024-W23"},{"count":3,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":4,"week":"2025-W05"},{"count":5,"week":"2025-W21"},{"count":17,"week":"2025-W22"},{"count":5,"week":"2025-W23"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W41"},{"count":1,"week":"2025-W42"},{"count":2,"week":"2026-W18"},{"count":1,"week":"2026-W28"},{"count":2,"week":"2026-W33"},{"count":1,"week":"2026-W42"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT04036682:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04036682:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:33122578","quote_policy":"short_quote_link_out"},{"id":"pubmed:37384848","quote_policy":"short_quote_link_out"},{"id":"pubmed:40450572","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2fykzdsl6dmpn5q3u2ew3gkn-3lqndxeggy22g","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4w7jzkpdswrg7tf4azxu3gsc-3lqkcco3yuf22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4ysesz2mn5ig5vitaq3qdjos-3lqaobhckhk2d","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7eeegxgy3hkpipqnlzr7na4c-3lgtocvk7kx2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7eeegxgy3hkpipqnlzr7na4c-3lqkawrecii2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7eeegxgy3hkpipqnlzr7na4c-3luke3hkfnt2o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7eeegxgy3hkpipqnlzr7na4c-3lyfg3kds5f2t","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3lgvgg4ixds2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mkkxclf7g22r","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ed55dgyglbcqmn5a5aayfrro-3lqkgsgcbss2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3lqkaspjjyw2s","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3lyffu7v7cz22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hslirr7h6d7livppaxty435b-3lqkbapmkip27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3lnifgabq4k2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3lps2wx32rb2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-lbvwy443zljv4ycy7kztkqfi-3lh4cxhgszk2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t7xptfbayvic6qufjdwujti7-3lbnpoio5fk2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xsr7lhrhirayqjpkc6ambiqo-3lv2evdpkpc26","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7335614269910056960","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1402193078639861762:637ac94c-bef1-489d-b33e-0555a9863f6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1529967728873857036:84eab52b-25a3-4b18-88d8-d250e63114f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532819197587345409:d0f27944-d508-4f26-9df7-3c616e81c7c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532819992294588418:92e3a798-3476-40b5-90c3-0a637717b54e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532828576466206721:20c8a106-404b-4037-b123-c0a0b3ad1d11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1532865635566354434:d28d8f7d-eed1-4bda-a5f1-30a96bf119b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533815464383500290:56c6299c-18aa-4dc0-bed0-216682cf3789","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1546602365968699394:cbfbbf83-57a8-42e6-9034-45c223c83cb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1674599968286310403:bc541ff2-47ae-4b59-91cb-e06e3df26eb0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1675711482082783232:e99f5d8c-3c34-4c55-b046-2f92f96898fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1676948528470564866:b8ac5cf8-7874-44a4-84ff-86f9c1253b85","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1678271622862753793:738d84e7-05cd-4bee-9f14-459533f10447","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1686036520044462080:7b940873-6d90-4c6c-b513-1a44f7b8233b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715280324836401398:dfb253d1-a580-4620-bc69-2c2665f469e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1792585282572685518:5fed8bfc-ee3a-42ba-a857-6134e6da8e89","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796859750858027190:93f17d8d-213c-4cc2-a236-d57f58cf4b54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796860385104134286:3401af16-ceef-4f12-b8d6-c6b04da61041","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796864751705743590:6a2a9fbf-b21b-4cb9-8e9c-e230e39062e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796875787850658145:70586b09-4caf-4ce6-8230-7e0889611b48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1796910488137376213:d4aadd13-8fef-4cf7-a312-1cc0437d3741","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797068208979284122:5a58ff69-3735-41e4-9b41-b02d753fc5a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797602562134376587:7f83943d-d36a-4d41-9606-112c6e00fd5e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797605380110844411:30eb67e3-536e-49cd-849d-c2745e1de22c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834819368305209460:aad2053b-516c-4151-bba9-0638dbfc1c49","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834869618495644089:f9e4bb0e-2c1c-4b99-aec1-bab488553620","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834869865980608667:0a3fd9a3-50d4-4d37-9bd9-722899edf276","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834870096952508911:27243cdb-561c-415a-8414-c12b53392e6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834870746893762832:fcd23eca-eeef-46be-82e2-d865c3471915","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835168286087983512:943b068f-d967-42d4-b359-7780b87ae093","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835217611174383678:a279f2e8-566f-462c-98ff-38d1ec885032","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835340506622226433:39ba7222-eaca-4c73-8b5a-c935eb2e8312","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1836012792580653536:d0491fcc-82f0-4527-a410-64b66bf6443f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1837096294646481354:58348c33-5a0e-49b8-b08b-469fa5846ea3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1860475082394734801:86975840-a9a7-4639-8421-f649a2888bce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884394040092774523:63d48dc4-3c48-416d-9827-8f90e3645acb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884534561960300632:97b5d59b-1457-4bf9-becc-2877d8187b56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884579774426997074:57e0abfa-066e-4b35-a72e-86fd0662610d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884645012056555822:48da73e1-43de-460d-bc5b-343a4b68244d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884650275639619911:497070dd-6cf6-4c25-b578-260c6a515b57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884655305302126606:a632c730-a597-4f7f-a9a1-6fdf1980dd06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1884664704221774315:c438bc7c-66c2-474b-bfb6-8b74269430e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1885093161166422031:529ad1da-d7bb-4b96-96f3-9c90ecdaa629","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1885131009600942550:129a94ab-fff0-4b83-9070-78bb6e2d5c34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1885388314288554106:98e46e7e-9893-420d-b137-660f48357753","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1885638165689516297:777b3d62-3303-4de5-9601-6b308892b139","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1886172829156045218:923aa6f4-b616-4289-aa83-fe8141b70ea5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1886438341656113553:69a175e3-71e5-4f79-9087-474b0486513c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887097588635291768:5a80573a-7090-4380-9945-9a0caec09aab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1892686650095882689:a13fc490-54c2-4751-a5d9-03b3acfd141f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1892801576571433151:ca825492-3e81-4ab1-8137-6d02e9d9b89f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1893692346224558483:0edeaba8-7579-405e-a647-0b94b164ca04","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1910696603091869971:90adf5e2-e173-487b-b236-26122e10d186","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915048098600194392:e485a8f6-7847-4937-ac80-6b209a8a132c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915048114505060439:a865f796-a92b-4df1-b279-cb98b55610ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915136276229218530:e8f8331c-63e4-483c-a7c2-3a7c8583d9bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915160158113849811:6fe22d93-d5e2-4f31-97ac-91559905f517","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925664406857236736:97572b1c-3d1c-4945-a072-01f5601339eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925664976930316652:dd23734a-0b88-4019-8523-0fad4fead8f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925673094946947441:af528bcb-5d7f-450a-ae5a-456455deaa50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925703833033863418:e3514807-2d9e-4bea-84ed-284f77bd467a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925733137784414463:94bca611-f571-4fbc-aee2-a04be5fe61c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925746163904295002:11593534-12de-479c-ab71-0f5a273b1c1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925879783629488494:c48af083-af55-44ba-8c4c-f84cb4f64fae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925901126957666604:095c63ec-3669-433b-807f-7a49398694a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925990694713254127:a3169f6f-1216-4a44-88e2-2ae50e18c839","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925998298659225965:dc93a31f-aca8-4572-80d7-8ba5c210e2f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926731421009191316:076f5aa9-788b-41c8-a035-b193cca36a7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926973309842837640:08652ebb-7865-4f35-91bf-fa1b0f0507f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1927411225388048464:fc42674a-b633-4d82-ae78-87697db09317","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1927772841585381409:3c4a81d0-163a-425b-aa11-95ddab49851f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928813724531564582:4834572f-18f6-4269-8742-35d85b2d9e7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929151879218409751:f78e8e7b-df12-4aa7-a9e6-93204c887066","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929151955907055625:509b330a-ca51-4038-8c7e-dd55047dfc7d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929151986391458237:4a237ccf-5117-48a1-bc70-e18d8a8c30f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929153460089266650:5ee02873-dae4-4592-a131-5d5a787e9d37","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929159375639474475:72bf70dc-15da-4a0c-95ce-41bb595ae171","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929167659750334591:6f1b1545-fca2-4dc9-8da5-5214e0e7a6f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929177963481698330:5452390b-c51b-43a4-8096-e289a67a5018","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929178042447823081:36d88bde-6f03-4126-8495-ac2909b1e54a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929178149696180522:f1ad68db-17a2-46ec-8e35-6927b5e7db2c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929178183124815934:c3de9a9a-0dd0-42f4-ab44-bde289138f48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929178429787689201:b6ac228c-6a76-45f5-802c-838809efc3d1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929178609798799422:a182b523-1157-4572-b33c-1f2974533e66","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929178810672689628:e616a1ba-f096-47cd-92ad-c0f197807ee8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929178965958144394:5884f8eb-332e-48dd-a516-3b2c32d8ebc3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929179028159610909:f16c91b4-f230-4fc4-b909-5c5db971ef10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929179148880109733:453d9799-36c8-433b-a0d1-cbd4e5f3927c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929179907247985086:78230f33-5c8d-4825-815a-3370b081abd8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929179981042565410:5de78097-28fb-4e66-95e4-ae6543c7fc38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929180263843602778:00fbf99f-1c3e-464d-9515-8bc51d1caa75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929181828000203214:eda70368-b7a8-43e9-b41c-61a379be3491","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929182321522946195:8c5083d5-99b8-4fea-ab36-8763c087be64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929182667712450774:82a43a8f-f605-4087-924e-e9c19f46a0c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929183610797756859:2ddd5662-ce08-4745-8179-02179b7989f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929186180144431412:54d2d049-dc38-41cc-ae0d-3b8f3a02b7f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929186280929218736:61c7abfe-7cca-4925-88dd-2a71837a58d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929186599184875969:5b5dfde8-0b50-469f-8d5f-68263dd2f68f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929241620366475583:cb05f4d0-9ae1-4cd7-92d4-c056455d7bdb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929242652261691631:ae9fb515-0c8a-4f55-8fd2-24968d782887","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929271988519936421:f1ae9d42-65a0-483b-9a16-04f97492ea6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929563297839292441:29cb0dad-134c-49c6-8d6d-cd938715e608","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929921100881756651:5f2d81ca-469e-4868-b955-41ae94f7e444","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930637552366887009:f3d3a621-1481-4ad5-a6e6-e60cb8487f63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1931072018214240320:6e902c78-31a2-42e1-b9f5-2597ff36e752","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1932421948874576330:764e3919-0afd-4d97-9893-c61517589b64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933862525839323195:c4ff418d-2a79-46b8-b7ee-340e02a6de2d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1947620630477869352:87221813-e98b-43ba-9e2c-9b7e228837b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1947623945269608638:80c1fff2-1846-47f5-a632-7e043ea07481","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1951326163688632662:4d2622d3-f1ae-40eb-b1d1-ed59459ca256","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1957727226964623397:db27ea91-20b9-4f50-91cb-f3182d876120","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965350168171348210:6e0c1a9a-eed4-4679-8c97-5d53fbfde7a6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965358169569591756:64c9caab-0191-4fc6-8a06-6e7194331077","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965412658154201134:cfa27363-95cd-4491-858c-c0a8e414ed25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1966874121641320836:b750c0aa-3f3b-48b0-afcc-4c806e4ecd97","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1972667178135544313:bd5280c7-1a2e-4a59-9e84-3dbbab77a376","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974492142077669556:c8757f1e-7b7a-4d74-bc08-2cfdf14b28fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1975719944886051167:4c5b7f04-745a-427c-8644-4cf845aab285","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979807613568356423:5fc3ccd2-b65b-4db9-bfa6-5d95274bc6fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1987797626482504121:4313d5f0-4091-423e-8206-587f76a1a7f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1988319464656445761:80c1e3db-9585-49f2-981e-3c0bf32648ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2003123361871024240:2d63593f-b484-4654-966f-57a4a7d994c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2013278526938493375:a7fdfdc0-a980-4f83-b7d1-69d08319390f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049140882692296941:7ebefd72-afd5-4d06-92ab-e5e51c369575","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049156430888898731:0b0a8d8f-4f31-45f9-b651-eaa6b65702ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049458734145880417:150b8b9e-5141-4fae-bfdd-804de8f59dda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2054366096891723949:c1fe8d2a-82c6-4707-b546-fa695273d5e5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2076007106462077102:7b1c9b42-bad7-4414-a687-5793ed16add3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087691527434760313:3f94d56c-579d-4485-bc9c-ea24b4255563","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088327395405087130:dcece138-0ae2-43c3-8077-30a4832a46e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111014401063243791:310f22e8-e7bf-4954-853a-d675bb961257","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:7gICdwbEjWQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:7r7tKgn7ZAc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:buqUKWmHQso","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:fkVcspQzgIo","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":18,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":130,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":153},"count":153,"evidence_window":{"end":"2026-10-17","start":"2021-06-08"},"retrieval_snapshot":"2026-11-10T21:53:48.308534Z","timeline":[{"count":1,"week":"2021-W23"},{"count":1,"week":"2022-W21"},{"count":4,"week":"2022-W22"},{"count":1,"week":"2022-W23"},{"count":1,"week":"2022-W28"},{"count":1,"week":"2022-W29"},{"count":1,"week":"2022-W30"},{"count":1,"week":"2023-W26"},{"count":2,"week":"2023-W27"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2023-W31"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2024-W21"},{"count":6,"week":"2024-W22"},{"count":2,"week":"2024-W23"},{"count":8,"week":"2024-W37"},{"count":3,"week":"2024-W38"},{"count":2,"week":"2024-W47"},{"count":15,"week":"2025-W05"},{"count":2,"week":"2025-W06"},{"count":3,"week":"2025-W08"},{"count":1,"week":"2025-W15"},{"count":5,"week":"2025-W17"},{"count":12,"week":"2025-W21"},{"count":39,"week":"2025-W22"},{"count":7,"week":"2025-W23"},{"count":3,"week":"2025-W24"},{"count":3,"week":"2025-W30"},{"count":2,"week":"2025-W31"},{"count":1,"week":"2025-W34"},{"count":6,"week":"2025-W37"},{"count":2,"week":"2025-W40"},{"count":1,"week":"2025-W41"},{"count":1,"week":"2025-W42"},{"count":2,"week":"2025-W46"},{"count":1,"week":"2025-W52"},{"count":1,"week":"2026-W04"},{"count":4,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W28"},{"count":2,"week":"2026-W33"},{"count":2,"week":"2026-W42"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":1,"linkedin_post":2,"other":0,"podcast":0,"publication":7,"registry":0,"regulatory":0,"x_thread":91,"x_video":0,"youtube":28}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: cln-081","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"reason":"Unmapped registry condition: EGFR Exon 20 Mutation","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"REZILIENT1","aliases":["REZILIENT1","A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy"],"brief_title":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","collaborators":["Taiho Oncology, Inc."],"conditions":["Non Small Cell Lung Cancer","EGFR Exon 20 Mutation"],"display_condition":"previously treated EGFR exon 20 insertion-positive metastatic NSCLC","display_interventions":[["zipalertinib"]],"enrollment":{"count":284,"type":"ESTIMATED"},"interventions":[{"name":"CLN-081","synonyms":["TAS6417; zipalertinib"],"type":"DRUG"}],"nct_id":"NCT04036682","official_title":"A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2025-10-13","type":"ACTUAL"},"primary_endpoints":[{"measure":"All Cohorts: The rate and severity of treatment emergent AEs.","timeFrame":"24 months"},{"measure":"All Cohorts: The rate and severity of DLTs.","timeFrame":"24 months"},{"measure":"Phase 2 Dose Expansion Cohorts: Overall response rate (ORR)","timeFrame":"24 months"},{"description":"Maximum Plasma Concentration \\[Cmax\\]","measure":"Module A: Pharmacokinetic (PK) parameter","timeFrame":"24 months"},{"description":"Area Under Curve \\[AUC\\]","measure":"Module A: Pharmacokinetic (PK) parameter","timeFrame":"24 months"},{"measure":"Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC)","timeFrame":"24 months"}],"registered_date":{"date":"2019-07-30","type":"ACTUAL"},"registry_last_updated":"2026-06-17","registry_url":"https://clinicaltrials.gov/study/NCT04036682","short_name":"REZILIENT1","short_name_basis":"registry_acronym","sponsor":"Cullinan Therapeutics Inc.","start_date":{"date":"2019-10-31","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1, phase2","study_ids":[{"id":"CLN-081-001","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}